ArriVent BioPharma Shares Plunge Over 48% After Lung Cancer Trial Fails
ArriVent BioPharma (AVBP) shares plummeted over 48% to an all-time low on Tuesday after the company announced its experimental lung-cancer treatment failed to meet the primary endpoint of a Phase 3 trial. This marks the stock's largest single-day decline.